RxDoctor Payments Data

Carlos Jimenez, MD

Nuclear Medicine · Rio Piedras, PRNPI 1609841667

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 64.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $309 and has fallen 70.1% since, to $92 in 2024.

$767in general payments, 2019–2025

Across 13 payments — averaging $59.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$495
  • Merck$125
  • Smith+Nephew$71
  • Osiris Therapeutics Inc.$48
  • Lantheus Medical Imaging, Inc.$28

What the payments were for

  • Food & beverage$767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 80th percentile of 20 nuclear medicine providers in Puerto Rico.

See all nuclear medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$453,715
Medicare patients
546
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium475$45,832
OzempicSemaglutide11$10,806
JanumetSitagliptin Phos/Metformin Hcl15$10,055
NorvascAmlodipine Besylate14$3,628
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,352
HumalogInsulin Lispro14$1,209
Rosuvastatin Calcium71$1,180
Glimepiride30$904
Atorvastatin Calcium60$602
Metoprolol Succinate35$567
Gabapentin39$492
Diclofenac Potassium12$429
Enalapril Maleate19$393
Glipizide11$359
Losartan Potassium28$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet$125$10,05515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 20 nuclear medicine providers in Puerto Rico.

Other nuclear medicine in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →